Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. (February 2017) - Tolaney, S.; Savulsky, C.; Aktan, G.; Xing, D.; Almonte, A.; Karantza, V.; Diab, S.